Somos una compañía global dedicada al cuidado de la salud, fundada en 1923 y con sede a las afueras de Copenhague, Dinamarca. Nuestro propósito es impulsar el cambio para vencer la diabetes y otras enfermedades crónicas graves como la obesidad, las enfermedades raras de la sangre y endocrinas.

Join Novo Nordisk for a life-changing career establishing and developing a world-class Global Business Service Centre in Mexico City. This will impact millions of people living with a chronic disease like diabetes and obesity.

Somos una compañía global dedicada al cuidado de la salud, fundada en 1923 y con sede a las afueras de Copenhague, Dinamarca. Nuestro propósito es impulsar el cambio para vencer la diabetes y otras enfermedades crónicas graves como la obesidad, las enfermedades raras de la sangre y endocrinas.

The right solution makes a world of difference for you and your patients. Dive deeper into the insights and science behind our exceptional solutions. 4600 Køge, . Denmark.

Discover Novo Nordisk Mexico's home page for information on their products, services, and patient programs.

EF: What role does innovation play for you in Mexico, and how is Novo Nordisk leveraging regional research and development? VS: We take pride in our commitment to innovation, ingrained in our DNA.

Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity, and rare blood and rare endocrine diseases. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure the diseases we treat.

Sep 5, 2024 · Valney Suzuki highlights his focus on expanding access to Novo Nordisk's innovations in Mexico, especially for vulnerable populations; the importance of ethical usage of the company's groundbreaking semaglutide-based treatments for diabetes and obesity; and Mexico's crucial role in Novo Nordisk’s global operations, not just as a market but ...

Feb 13, 2014 · With the increasing severity of diabetes in Mexico, Novo Nordisk is committed more than ever to combating the disease, and will continue to work hard to be the leader in the Mexican market. Innovative products for diabetes, growth hormone deficiencies and haemophilia.

EF: Innovation is key to Novo Nordisk, and Mexico plays a key role for the company in clinical trials. Does Mexico have the potential to establish itself as an innovation hub at a Latin American level, and how can Novo participate? VS: Novo Nordisk invests a lot in innovation.